Alzheimer's advocacy organizations have praised the FDA's approval of the new treatment for the debilitating disease, but they have equally condemned the Centers for Medicare and Medicaid Services for attaching significant burdens to access the care.
The Centers for Medicare and Medicaid Services announced on Thursday that, for Medicare to cover these expensive treatments, Medicare patients must be diagnosed with amyloid plaques on the brain and be treated by a physician who would be required to upload patient information into a federal database to monitor the real-world efficacy of the treatments.
Coverage for Leqembi falls under Medicare Part B, as the treatment is administered in a facility, with a 20% patient co-pay depending upon the patient's supplemental insurance, making the out-of-pocket costs for the treatment over $5,000 annually. The Alzheimer's Association announced that, although it applauds the FDA's approval of Leqembi and CMS's steps to cover the drug, Medicare needs to do more to ease access to life-altering care for those with this terminal illness. Of chief concern is the mandatory participation in the federal registry.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Leer más »
FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverageDespite Medicare coverage, drug may remain out of reach for many patients, policy experts say
Leer más »
Alzheimer’s drug Leqembi granted full FDA approval and that means Medicare will pay for itU.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease.
Leer más »
FDA approves Alzheimer’s treatment Leqembi, allowing for Medicare coverageThe FDA gave it conditional approval in January based on early results suggesting the drug could modestly slow cognitive decline. FDA officials said Thursday that the drug’s benefits have now been confirmed.
Leer más »
Op-ed: Medicare agency limiting access to Alzheimer’s treatmentCommentary: A new treatment for Alzheimer’s disease, lecanemab, will likely receive traditional FDA approval on Thursday. Unfortunately, the Centers for Medicare & Medicaid Services is closing the door to ready access to this new treatment.
Leer más »
FDA approves use of Leqembi to treat Alzheimer's patientsFDA approves use of Leqembi Alzheimer\u0027s patients
Leer más »